Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Company profile
Ticker
XENT
Exchange
Website
CEO
Thomas West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SINEXUS INC
SEC CIK
XENT stock data
Latest filings (excl ownership)
POSASR
Automatic shelf registration (post-effective amendment)
12 Sep 22
RW WD
Withdrawal of registration withdrawal request
12 Sep 22
15-12B
Securities registration termination
23 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
19 May 22
EFFECT
Notice of effectiveness
18 May 22
25-NSE
Exchange delisting
13 May 22
RW
Registration withdrawal request
13 May 22
POS AM
Prospectus update (post-effective amendment)
13 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 May 22
Transcripts
XENT
Earnings call transcript
2021 Q1
10 May 21
XENT
Earnings call transcript
2020 Q4
9 Mar 21
XENT
Earnings call transcript
2020 Q3
2 Nov 20
XENT
Earnings call transcript
2020 Q3
2 Nov 20
XENT
Earnings call transcript
2020 Q3
2 Nov 20
XENT
Earnings call transcript
2020 Q2
9 Aug 20
XENT
Earnings call transcript
2020 Q1
11 May 20
XENT
Earnings call transcript
2019 Q4
24 Feb 20
XENT
Earnings call transcript
2019 Q3
1 Nov 19
XENT
Earnings call transcript
2019 Q2
2 Aug 19
Latest ownership filings
SC 13G/A
Versor Investments LP
10 Feb 23
4
Neil A Hattangadi
16 May 22
4
RICHARD A MEIER
16 May 22
4
Reyna M Fernandez
16 May 22
4
PATRICK A BRODERICK
16 May 22
4
KIERAN GALLAHUE
16 May 22
4
Elisabeth Sandoval
16 May 22
4
Thomas A. West
16 May 22
4
Teresa L. Kline
16 May 22
4
Cynthia L Lucchese
16 May 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.58 mm | 42.58 mm | 42.58 mm | 42.58 mm | 42.58 mm | 42.58 mm |
Cash burn (monthly) | 4.57 mm | (no burn) | 8.89 mm | 12.43 mm | 8.95 mm | 5.80 mm |
Cash used (since last report) | 113.58 mm | n/a | 221.10 mm | 309.05 mm | 222.64 mm | 144.13 mm |
Cash remaining | -71.00 mm | n/a | -178.52 mm | -266.47 mm | -180.06 mm | -101.55 mm |
Runway (months of cash) | -15.5 | n/a | -20.1 | -21.4 | -20.1 | -17.5 |
Institutional ownership, Q1 2023
17.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 146.02 mm |
Total shares | 6.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 4.44 mm | $101.64 mm |
Integrated Core Strategies | 1.63 mm | $44.39 mm |